Cargando…
Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review
INTRODUCTION: Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patie...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859842/ https://www.ncbi.nlm.nih.gov/pubmed/36331754 http://dx.doi.org/10.1007/s12325-022-02351-7 |
_version_ | 1784874450713313280 |
---|---|
author | Lohsiriwat, Varut Sheikh, Parvez Bandolon, Robert Ren, Dong-Lin Roslani, April Camilla Schaible, Kassandra Freitag, Andreas Martin, Monique Yaltirik, Pelin Godeberge, Philippe |
author_facet | Lohsiriwat, Varut Sheikh, Parvez Bandolon, Robert Ren, Dong-Lin Roslani, April Camilla Schaible, Kassandra Freitag, Andreas Martin, Monique Yaltirik, Pelin Godeberge, Philippe |
author_sort | Lohsiriwat, Varut |
collection | PubMed |
description | INTRODUCTION: Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. METHODS: Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. RESULTS: The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (n = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. CONCLUSION: The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02351-7. |
format | Online Article Text |
id | pubmed-9859842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-98598422023-01-22 Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review Lohsiriwat, Varut Sheikh, Parvez Bandolon, Robert Ren, Dong-Lin Roslani, April Camilla Schaible, Kassandra Freitag, Andreas Martin, Monique Yaltirik, Pelin Godeberge, Philippe Adv Ther Review INTRODUCTION: Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD. METHODS: Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews. RESULTS: The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (n = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments. CONCLUSION: The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02351-7. Springer Healthcare 2022-11-04 2023 /pmc/articles/PMC9859842/ /pubmed/36331754 http://dx.doi.org/10.1007/s12325-022-02351-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Lohsiriwat, Varut Sheikh, Parvez Bandolon, Robert Ren, Dong-Lin Roslani, April Camilla Schaible, Kassandra Freitag, Andreas Martin, Monique Yaltirik, Pelin Godeberge, Philippe Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title_full | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title_fullStr | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title_full_unstemmed | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title_short | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
title_sort | recurrence rates and pharmacological treatment for hemorrhoidal disease: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859842/ https://www.ncbi.nlm.nih.gov/pubmed/36331754 http://dx.doi.org/10.1007/s12325-022-02351-7 |
work_keys_str_mv | AT lohsiriwatvarut recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT sheikhparvez recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT bandolonrobert recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT rendonglin recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT roslaniaprilcamilla recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT schaiblekassandra recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT freitagandreas recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT martinmonique recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT yaltirikpelin recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview AT godebergephilippe recurrenceratesandpharmacologicaltreatmentforhemorrhoidaldiseaseasystematicreview |